Brentuximab vedotin in patients who are ineligible for autologous stem cell transplant with relapsed or refractory Hodgkin lymphoma: a United Kingdom and Germany retrospective study.
Authors
Brockelmann, PZagadailov, E
Corman, S
Hagan, M
Chirikov, V
Johnson, C
Macahilig, C
Seal, B
Dalal, M
Illidge, Timothy M
Affiliation
Department I of Internal Medicine and German Hodgkin Study Group (GHSG), University Hospital of Cologne, GermanyIssue Date
2016